Trending Now
Latest News
Kedrion and Kamada Announce FDA Approval of KedRAB Label Update, Confirming...
FORT LEE, N.J. and REHOVOT, Israel, June 02, 2021 (GLOBE NEWSWIRE) -- Kedrion Biopharma and Kamada Ltd. (NASDAQ & TASE: KMDA), two leading biopharmaceutical...
Alexion Announces FDA Approval of Ultomiris (ravulizumab-cwvz) for Children and Adolescents...
BOSTON--(BUSINESS WIRE)--Jun. 7, 2021-- Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced the U.S. Food and Drug Administration (FDA) has approved the expanded use of Ultomiris (ravulizumab-cwvz) to include children (one...
More
Kedrion and Kamada Announce FDA Approval of KedRAB Label Update, Confirming Safety and Effectiveness...
FORT LEE, N.J. and REHOVOT, Israel, June 02, 2021 (GLOBE NEWSWIRE) -- Kedrion Biopharma and Kamada Ltd. (NASDAQ & TASE: KMDA), two leading biopharmaceutical...
Alexion Announces FDA Approval of Ultomiris (ravulizumab-cwvz) for Children and Adolescents with Paroxysmal Nocturnal...
BOSTON--(BUSINESS WIRE)--Jun. 7, 2021-- Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced the U.S. Food and Drug Administration (FDA) has approved the expanded use of Ultomiris (ravulizumab-cwvz) to include children (one...
U.S. Food and Drug Administration Approves New Formulation of Epclusa, Expanding Pediatric Indication to...
FOSTER CITY, Calif.--(BUSINESS WIRE)--Jun. 10, 2021-- Gilead Sciences, Inc. (Nasdaq: GILD) announced today that the U.S. Food and Drug Administration (FDA) has approved an...
Inflated savings, hidden costs: How vendors who “carve-out” specialty benefits fail to deliver promised...
Specialty medications – high-cost medications that treat complex, chronic conditions – have become a key driver of overall prescription drug spend. In fact, according...
In Western Europe, hospitals look to quell the mental health epidemic among staff
The Covid-19 pandemic has taken an incalculable toll on mental and behavioral health the world over. But none have been more severely affected than...